Overview

This study is a Phase I, open-label, single-arm clinical trial to evaluate the safety, pharmacokinetics, and preliminary efficacy of GK01 in patients with advanced solid tumors.

Eligibility

1. Ability to understand and sign a written informed consent document；
2. At the date of signing ICF, 18 ~70 years old, male or female；
3. Histopathological confirmed advanced solid tumor patients who have failed to

   standard treatment or intolerance with standard treatment；

4. There is at least one resectable tumor lesion that has not received radiation

   therapy or other local therapies;

5. At least one measurable lesion at baseline per RECIST version 1.1；
6. The expected survival time is more than 12 weeks;
7. ECOG 0-1 points;
8. Adequate organ functions